SEP 17·SEC EDGARLow
Zhou Rong sold $239K of AMPH
Zhou Rong (SENIOR EVP, PRODUCTION CENTER) sold 10,000 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $23.94 ($0.24M total) on 2026-09-16.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$AMPH
Amphastar Pharmaceuticals, Inc.
AlphAI earnings readsecond quarter 2026 · AUG 6Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $AMPHvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AMPH in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $343K 2 txs
PETERS WILLIAM J1× · $103K
10b5-1 share of filings50%
Top stories · $AMPHMore →
SEP 1·stocktitan.net
Amphastar (NASDAQ: AMPH) VP plans Rule 144 stock sale led by 10,000-share option exercise
Amphastar Pharmaceuticals (AMPH) VP Rong Zhou plans to sell 10,000 shares, including 10,000 from an option exercise and smaller lots from the ESPP. The sale is under Rule 144, with UBS Financial Services acting as attorney-in-fact. The largest block is 10,000 shares.
AUG 21·finance.yahoo.com
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
AMPH sentiment & insider activity
Recent AMPH coverage spans earnings, insider activity and financial news.
In the last 30 days, AMPH insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($343K). The most active reporter was PETERS WILLIAM J, CFO, EVP & TREASURER, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving AMPH
Insider sale by a senior executive may signal weak confidence, but the amount is modest.
The filing signals potential new supply of AMPH shares, which could modestly pressure the stock price.
Strong earnings beat drives significant short‑term rally.
The filing indicates a near-term, pre-planned insider sale that can add incremental float and weigh on sentiment, though the disclosed size is modest versus shares outstanding.
Earnings were received positively, with both EPS and revenue beats supporting a modest upward reaction.
AlphAI scores every news story that mentions AMPH with an AI model for sentiment and relevance, and aggregates insider trades from Amphastar Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AMPH
Score
Zhou Rong sold $239K of AMPH
Zhou Rong (SENIOR EVP, PRODUCTION CENTER) sold 10,000 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $23.94 ($0.24M total) on 2026-09-16.
1 min readAmphastar (NASDAQ: AMPH) VP plans Rule 144 stock sale led by 10,000-share option exercise
Amphastar Pharmaceuticals (AMPH) VP Rong Zhou plans to sell 10,000 shares, including 10,000 from an option exercise and smaller lots from the ESPP. The sale is under Rule 144, with UBS Financial Services acting as attorney-in-fact. The largest block is 10,000 shares.
1 min read
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
3 min readAmphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise
Amphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.
2 min read
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks
A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;
6 min read
Amphastar (AMPH) Q2 2026 Earnings Call Transcript
Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.
6 min read
The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call
Amphastar Pharmaceuticals (AMPH) reported Q2 revenue of $183.9M vs $180.3M estimates and adjusted EPS of $0.91 vs $0.61, citing demand for BAQSIMI and Primatene MIST and the launch of ipratropium bromide. Analysts asked about R&D/SG&A, IMS FDA warning letter, business development, and margins for insulin aspart biosimilar.
7 min readPRINS RICHARD K sold $162K of AMPH
PRINS RICHARD K sold 7,973 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $20.30 ($0.16M total) on 2026-08-11.
2 min readAMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
Amphastar Pharmaceuticals said it expects higher operating expenses in coming quarters due to remediation costs at its IMS facility, partly offset by shifting capital spending from other sites. Management highlighted progress in its development pipeline, including an insulin aspart biosimilar targeted for commercialization in 2027, and expects mid- to high-single-digit sales growth despite competition.
5 min read
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.
4 min read